SGLT2 Inhibitors: Slowing of Chronic Kidney Disease Progression in Type 2 Diabetes David C. WheelerJune Jamesas part of the Improving Diabetes Steering Committee Review Open access 29 September 2020 Pages: 2757 - 2774
Considerations for Insulin-Treated Type 2 Diabetes Patients During Hospitalization: A Narrative Review of What We Need to Know in the Age of Second-Generation Basal Insulin Analogs Sherwin C. D’SouzaDavida F. Kruger Review Open access 30 September 2020 Pages: 2775 - 2790
Kidney Disease in Type 2 Diabetes Mellitus and Benefits of Sodium-Glucose Cotransporter 2 Inhibitors: A Consensus Statement Ajitesh RoyAnimesh MaitiWorking Group of the Endocrine Society of Bengal Review Open access 06 October 2020 Pages: 2791 - 2827
Diabetes Care During Hajj Shehla ShaikhHamid AshrafSanjay Kalra Review Open access 15 October 2020 Pages: 2829 - 2844
Effects of DPP-4 Inhibitors on Blood Glucose Variability in Japanese Patients with Type 2 Diabetes on Maintenance Hemodialysis: A Prospective Observational Exploratory Study Tomomi Ishikawa-TanakaMichihiro HosojimaIchiei Narita Original Research Open access 30 September 2020 Pages: 2845 - 2861
Does Roux-en-Y Construction Really Bring Benefit of Type 2 Diabetes Mellitus Remission After Gastrectomy in Patients with Gastric Cancer? A Systematic Review and Meta-Analysis Dong PengYu-Xi ChengWei Zhang Original Research Open access 01 October 2020 Pages: 2863 - 2872
Pre-Gestational Diabetes and Pregnancy Outcomes Dalal S. AliRecie DavernMensud Hatunic Original Research Open access 03 October 2020 Pages: 2873 - 2885
Adherence to the National Guidelines for Follow-Up Protocol in Subjects with Type 2 Diabetes Mellitus in Greece: The GLANCE Study Nikolaos PapanasMoses ElisafNikolaos Tentolouris Original Research Open access 03 October 2020 Pages: 2887 - 2908
Reduced Rates of Hypoglycemia in Type 1 or Type 2 Diabetes After Switching to Insulin Degludec: Results from the Italian Cohort of the ReFLeCT Study Gian Paolo FadiniCarla GiordanoThe REFLECT Italian Study Group Original Research Open access 03 October 2020 Pages: 2909 - 2920
Implementation of Empagliflozin in Patients with Diabetes Mellitus Type 2 and Established Cardiovascular Disease: Estimation of 5-Year Survival and Costs in Sweden Lars BernfortMagnus HusbergLars-Åke Levin Original Research Open access 06 October 2020 Pages: 2921 - 2930
Quality of Life and Utility Values for Cost-Effectiveness Modeling in Japanese Patients with Type 2 Diabetes Hitoshi IshiiHiroshi TakamuraBruce Crawford Original Research Open access 14 October 2020 Pages: 2931 - 2943
Efficacy and Safety of Tofogliflozin and Ipragliflozin for Patients with Type-2 Diabetes: A Randomized Crossover Study by Flash Glucose Monitoring Yuji KawaguchiJun SawaYasuro Kumeda Original Research Open access 15 October 2020 Pages: 2945 - 2958
Quality-of-Life Comparison of Dapagliflozin Versus Dipeptidyl Peptidase 4 Inhibitors in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial (J-BOND Study) Hitoshi IshiiHiroki NakajimaDai Shimono Original Research Open access 15 October 2020 Pages: 2959 - 2977
A Coloured Pen Needle Education System Improves Insulin Site Rotation Habits: Results of a Randomized Study Lori D. BerardSherri A. PockettRick L. Siemens Original Research Open access 16 October 2020 Pages: 2979 - 2991
Insulin Pump Therapy Issues Among Adults with Type 1 Diabetes Mellitus in Saudi Arabia: A Retrospective Study Yousef Al-SalehFajr Al MotairiNasser M. Al-Daghri Original Research Open access 17 October 2020 Pages: 2993 - 3001
Sodium–Glucose Cotransporter 2 Inhibitors and Major COVID-19 Outcomes: Promising Mechanisms, Conflicting Data, and Intriguing Clinical Decisions Dimitrios PatouliasChristodoulos PapadopoulosMichael Doumas Letter Open access 14 October 2020 Pages: 3003 - 3005
A Response To: Sodium–Glucose Cotransporter 2 Inhibitors and Major COVID-19 Outcomes: Promising Mechanisms, Conflicting Data, and Intriguing Clinical Decisions Antonio C. BossiFranco ForloniPaolo L. Colombelli Letter Open access 14 October 2020 Pages: 3007 - 3009
Correction to: Safety and Efficacy of Exenatide Once Weekly in Participants with Type 2 Diabetes and Stage 2/3 Chronic Kidney Disease Cristian GujaJuan P. FríasSerge A. Jabbour Correction Open access 04 October 2020 Pages: 3011 - 3013